Short answer
Merck & Co. (MRK) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $18.1B (up 4.7% year over year) with net income of $5.1B.
Q3 2026 key financials · XBRL
- Revenue
- $18.1B
- +4.7% YoY · +8.9% QoQ
- Net income
- $5.1B
- −12.4% YoY · +479.4% QoQ
- EPS (diluted)
- $2.05
- −11.3% YoY · +479.6% QoQ
Source: XBRL data from the Merck & Co. (MRK) Q3 2026 10-Q on SEC EDGAR. USD.
Merck & Co. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $18.1B, up 5% YoY from $17.3B, driven by oncology, cardiometabolic, respiratory, specialty and animal health
- Gross margin 72.9% vs 77.7% YoY, pressured by amortization, restructuring costs and Verona inventory step-up
- Best performer: Winrevair sales up 93%; worst: Lagevrio sales down 88% in the quarter
- Cash and investments $11.3B vs $15.5B at year-end; operating cash flow $15.8B vs $13.6B YoY
- Outlook: pricing pressure, generic competition and government cost containment expected to continue reducing sales and profits
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Merck & Co. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.